Everything you care about in one place

Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.

Get Feeder
← Find more feeds

investor.lilly.com

Eli Lilly and Company News Releases

Get the latest updates from Eli Lilly and Company News Releases directly as they happen.

Follow now 324 followers

Latest posts

Last updated about 1 hour ago

Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies

about 1 hour ago

U.S. Food and Drug Administration Issues Complete Response Letter for Lebrikizumab Based on Inspection Findings at Third-Party Manufacturer

1 day ago

Lilly Welcomes Request from Senators About Insulin Affordability Programs

4 days ago

US FDA approves Jardiance® for the treatment of adults with chronic kidney disease

11 days ago

Lilly Statement on Mounjaro® (tirzepatide) Compounding Litigation

14 days ago

Lilly to Participate in Morgan Stanley 21st Annual Global Healthcare Conference

about 1 month ago

Lilly's Retevmo® (selpercatinib) Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer

about 1 month ago

Lilly Completes Acquisition of Versanis Bio

about 2 months ago

Lilly Completes Acquisition of Sigilon Therapeutics

about 2 months ago

Lilly Completes Acquisition of DICE Therapeutics

about 2 months ago

Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline Advancements

about 2 months ago

Lilly's Retevmo® (selpercatinib) is the First Targeted Therapy to Demonstrate Superior Progression-Free Survival Compared to a PD-1 Inhibitor Plus Chemotherapy for Adults with Newly-Diagnosed Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung

2 months ago

Sign up to continue

Try Feeder for free

Everything you care about in one place

Try Feeder now